Daniel V.T. Catenacci

16.8k total citations · 4 hit papers
167 papers, 6.8k citations indexed

About

Daniel V.T. Catenacci is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Daniel V.T. Catenacci has authored 167 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Oncology, 85 papers in Pulmonary and Respiratory Medicine and 50 papers in Surgery. Recurrent topics in Daniel V.T. Catenacci's work include Gastric Cancer Management and Outcomes (71 papers), Cancer Genomics and Diagnostics (34 papers) and Pancreatic and Hepatic Oncology Research (33 papers). Daniel V.T. Catenacci is often cited by papers focused on Gastric Cancer Management and Outcomes (71 papers), Cancer Genomics and Diagnostics (34 papers) and Pancreatic and Hepatic Oncology Research (33 papers). Daniel V.T. Catenacci collaborates with scholars based in United States, South Korea and Japan. Daniel V.T. Catenacci's co-authors include Hyun Cheol Chung, Yung‐Jue Bang, Kei Muro, Jeffrey S. Ross, Siraj M. Ali, Talia Golan, Do‐Youn Oh, Adrian Murphy, Eric Van Cutsem and Mitesh J. Borad and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

In The Last Decade

Daniel V.T. Catenacci

161 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

2020 975 citations Ghassan K. Abou‐Alfa, Vaibhav Sahai et al. profile →
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

2016 848 citations Kei Muro, Hyun Cheol Chung et al. profile →
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

2019 441 citations Alexa B. Schrock, Joseph Chao et al. Annals of Oncology profile →
Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline

2020 181 citations Daniel V.T. Catenacci et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel V.T. Catenacci United States	37	4.1k	2.9k	2.8k	1.5k	1.2k	167	6.8k
Christelle de la Fouchardière France	36	7.8k 1.9×	2.8k 1.0×	2.6k 0.9×	1.7k 1.1×	2.8k 2.3×	191	10.9k
Kyoung‐Mee Kim South Korea	49	3.4k 0.8×	4.0k 1.4×	2.4k 0.9×	2.0k 1.3×	1.3k 1.1×	313	8.3k
Alexa B. Schrock United States	41	3.7k 0.9×	3.1k 1.1×	1.0k 0.4×	1.7k 1.1×	1.8k 1.4×	259	6.0k
Catherine Delbaldo France	20	6.3k 1.6×	2.7k 0.9×	1.6k 0.6×	1.8k 1.2×	2.2k 1.8×	48	8.3k
Rachna T. Shroff United States	35	4.2k 1.0×	1.9k 0.7×	3.4k 1.2×	1.6k 1.0×	1.4k 1.1×	172	6.4k
Magali Svrcek France	36	3.2k 0.8×	1.2k 0.4×	1.4k 0.5×	723 0.5×	822 0.7×	132	4.8k
Samuel J. Klempner United States	39	3.3k 0.8×	2.2k 0.8×	826 0.3×	1.7k 1.1×	1.3k 1.1×	197	5.4k
Allen Lee Cohn United States	38	4.7k 1.2×	2.4k 0.8×	875 0.3×	1.5k 1.0×	1.3k 1.0×	159	6.9k
Alan Anthoney United Kingdom	28	3.9k 1.0×	2.6k 0.9×	3.9k 1.4×	1.5k 1.0×	1.0k 0.9×	108	6.6k
Talia Golan Israel	39	5.4k 1.3×	1.7k 0.6×	975 0.4×	2.0k 1.3×	2.3k 1.9×	170	7.2k

Countries citing papers authored by Daniel V.T. Catenacci

Since Specialization

Citations

This map shows the geographic impact of Daniel V.T. Catenacci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel V.T. Catenacci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel V.T. Catenacci more than expected).

Fields of papers citing papers by Daniel V.T. Catenacci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel V.T. Catenacci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel V.T. Catenacci. The network helps show where Daniel V.T. Catenacci may publish in the future.

Co-authorship network of co-authors of Daniel V.T. Catenacci

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel V.T. Catenacci. A scholar is included among the top collaborators of Daniel V.T. Catenacci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel V.T. Catenacci. Daniel V.T. Catenacci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Tianxia, Osamu Kikuchi, Jin Zhou, et al.. (2023). Developing SHP2-based combination therapy for KRAS-amplified cancer. JCI Insight. 8(3). 7 indexed citations

Huffman, Brandon M., Vasily N. Aushev, Joseph Chao, et al.. (2022). Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. JCO Precision Oncology. 6(6). e2200420–e2200420. 36 indexed citations

Vogel, Arndt, Vaibhav Sahai, Antoine Hollebecque, et al.. (2022). P18 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202. Abstracts. A44.1–A44. 1 indexed citations

Wainberg, Zev A., Peter C. Enzinger, Yoon‐Koo Kang, et al.. (2021). Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).. Journal of Clinical Oncology. 39(3_suppl). 160–160. 63 indexed citations

Catenacci, Daniel V.T., Minori Koshiji Rosales, Hyun Cheol Chung, et al.. (2021). P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer. Annals of Oncology. 32. S146–S146. 1 indexed citations

Chau, Ian, Kerry Culm-Merdek, Johanna C. Bendell, et al.. (2021). 1386P Phase II study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (pembro) in advanced gastric or gastroesophageal junction (GEJ) cancer. Annals of Oncology. 32. S1050–S1051. 3 indexed citations

Zhou, Katherine I., Bryan Peterson, Anthony V. Serritella, et al.. (2020). Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. Clinical Cancer Research. 26(24). 6453–6463. 117 indexed citations

Reizine, Natalie, Bryan Peterson, Stephanie Moya, et al.. (2020). Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1–Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti–PD-1 Monoclonal Antibody Therapy. JCO Precision Oncology. 4(4). 1180–1186. 3 indexed citations

Catenacci, Daniel V.T., Minori Koshiji Rosales, Hyun Cheol Chung, et al.. (2020). MAHOGANY: Margetuximab Combination in HER2+ Unresectable/metastatic Gastric/gastroesophageal Junction Adenocarcinoma. Future Oncology. 17(10). 1155–1164. 81 indexed citations

10.

Maron, Steven B., Leah M. Chase, Samantha Lomnicki, et al.. (2019). Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. Clinical Cancer Research. 25(23). 7098–7112. 147 indexed citations

11.

Falchook, Gerald S., Razelle Kurzrock, Hesham M. Amin, et al.. (2019). First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research. 26(6). 1237–1246. 67 indexed citations

12.

Catenacci, Daniel V.T., Anteneh Tesfaye, Eric Cheung, et al.. (2019). Bemarituzumab With Modified Folfox6 For Advanced Fgfr2-Positive Gastroesophageal Cancer: Fight Phase Iii Study Design. Future Oncology. 15(18). 2073–2082. 56 indexed citations

13.

Maron, Steven B., Lindsay Alpert, Heewon Kwak, et al.. (2018). Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR -Amplified Gastroesophageal Adenocarcinoma. Cancer Discovery. 8(6). 696–713. 79 indexed citations

14.

Hong, David S., Patricia LoRusso, Omid Hamid, et al.. (2018). Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 25(8). 2403–2413. 42 indexed citations

15.

Marsh, Robert, Marina Talamonti, Marshall S. Baker, et al.. (2017). Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. Journal of Surgical Oncology. 117(3). 354–362. 26 indexed citations

16.

Maron, Steven B. & Daniel V.T. Catenacci. (2017). Update on Gastroesophageal Adenocarcinoma Targeted Therapies. Hematology/Oncology Clinics of North America. 31(3). 511–527. 14 indexed citations

17.

Wainberg, Zev A., Shadia I. Jalal, Kei Muro, et al.. (2017). KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer. Annals of Oncology. 28. v616–v617. 30 indexed citations

18.

Salgia, Ravi, Premal H. Patel, John Bothos, et al.. (2014). Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 20(6). 1666–1675. 56 indexed citations

19.

Catenacci, Daniel V.T., Wei‐Li Liao, Sheeno Thyparambil, et al.. (2014). Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue. PLoS ONE. 9(7). e100586–e100586. 40 indexed citations

20.

Catenacci, Daniel V.T., Mark Kozloff, Hedy L. Kindler, & Blasé N. Polite. (2011). Personalized Colon Cancer Care in 2010. Seminars in Oncology. 38(2). 284–308. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact